Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients. …
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 Australian Biotech
Latest Video
New Stories
-
Vinnies named inaugural partner of Pharmacy Guild Foundation
August 18, 2026 - -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - -
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 - - Australian Biotech -
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - - Australian Biotech -
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - - Latest News -
Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?
August 17, 2026 - - Latest News